Live Breaking News & Updates on Calliditas Therapeutics Ab Publ

Stay updated with breaking news from Calliditas therapeutics ab publ . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $21.25, but opened at $22.00. Calliditas Therapeutics AB (publ) shares last traded at $22.48, with a volume of 1,043 shares changing hands. Analyst Ratings Changes Separately, HC Wainwright reiterated a “buy” […] ....

Optiver Holding , Deutsche Bank , Tower Research Capital , Calliditas Therapeutics , Get Free Report , Research Capital , Street Group , Calliditas Therapeutics Ab Publ , Nasdaq Calt ,

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.08

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $22.08, but opened at $21.03. Calliditas Therapeutics AB (publ) shares last traded at $21.11, with a volume of 1,622 shares traded. Analyst Upgrades and Downgrades Separately, HC Wainwright reissued a […] ....

Deutsche Bank , Tower Research Capital , Optiver Holding , Company Profile , Calliditas Therapeutics , Get Free Report , Street Group , Research Capital , Calliditas Therapeutics Ab Publ , Nasdaq Calt ,

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Up 4.5%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report)’s stock price was up 4.5% on Monday . The company traded as high as $21.96 and last traded at $21.96. Approximately 3,068 shares changed hands during trading, a decline of 63% from the average daily volume of 8,219 shares. The stock had previously closed at $21.01. […] ....

Company Profile , Tower Research Capital , Optiver Holding , Deutsche Bank , Calliditas Therapeutics , Get Free Report , Street Group , Research Capital , Calliditas Therapeutics Ab Publ , Nasdaq Calt ,

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) to Post FY2024 Earnings of $0.24 Per Share, Lifesci Capital Forecasts

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) – Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Calliditas Therapeutics AB (publ) in a research note issued to investors on Wednesday, February 21st. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings of $0.24 per share […] ....

Tower Research Capital , Optiver Holding , Deutsche Bank , Company Profile , Calliditas Therapeutics , Free Report , Lifesci Capital , Get Free Report , Street Group , Research Capital , Calliditas Therapeutics Ab Publ , Nasdaq Calt , Earnings Estimates ,

HC Wainwright Reaffirms "Buy" Rating for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

HC Wainwright restated their buy rating on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) in a research note published on Thursday, Benzinga reports. They currently have a $50.00 price target on the stock. Calliditas Therapeutics AB (publ) Price Performance Calliditas Therapeutics AB (publ) stock opened at $20.04 on Thursday. The stock’s 50 […] ....

Optiver Holding , Deutsche Bank , Tower Research Capital , Company Profile , Calliditas Therapeutics , Free Report , Get Free Report , Street Group , Research Capital , Calliditas Therapeutics Ab Publ , Nasdaq Calt , Reiterated Rating , Hc Wainwright ,